Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis

• Published in: Scientific reports Vol. 10; no. 1; pp. 1 - 14
• Main Authors: Parvez, Shabi, Yadagiri, Ganesh, Gedda, Mallikarjuna Rao, Singh, Aakriti, Singh, Om Prakash, Verma, Anurag, Sundar, Shyam, Mudavath, Shyam Lal
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 22-07-2020; Nature Publishing Group; Nature Portfolio
• Subjects: 639/925/352; 692/699/255; Amphotericin B; Antifungal agents; Biocompatibility; Confocal microscopy; Cytotoxicity; Drug delivery; Evaporation; Humanities and Social Sciences; Internalization; Intestine; Lipids; Macrophages; Microscopy; Miltefosine; multidisciplinary; Nanoparticles; Parasites; Parasitic diseases; Paromomycin; Scanning electron microscopy; Science; Science (multidisciplinary); Transmission electron microscopy; Vector-borne diseases; Visceral leishmaniasis; β-Cyclodextrin
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-69276-5

The development of an effective oral therapeutics is an immediate need for the control and elimination of visceral leishmaniasis (VL). We exemplify the preparation and optimization of 2-hydroxypropyl-β-cyclodextrin (HPCD) modified solid lipid nanoparticles (SLNs) based oral combinational cargo system of Amphotericin B (AmB) and Paromomycin (PM) against murine VL. The emulsion solvent evaporation method was employed to prepare HPCD modified dual drug-loaded solid lipid nanoparticles (m-DDSLNs). The optimized formulations have a mean particle size of 141 ± 3.2 nm, a polydispersity index of 0.248 ± 0.11 and entrapment efficiency for AmB and PM was found to be 96% and 90% respectively. The morphology of m-DDSLNs was confirmed by scanning electron microscopy and transmission electron microscopy. The developed formulations revealed a sustained drug release profile upto 57% (AmB) and 21.5% (PM) within 72 h and were stable at both 4 °C and 25 °C during short term stability studies performed for 2 months. Confocal laser scanning microscopy confirmed complete cellular internalization of SLNs within 24 h of incubation. In vitro cytotoxicity study against J774A.1 macrophage cells confirmed the safety and biocompatibility of the developed formulations. Further, m-DDSLNs did not induce any hepatic/renal toxicities in Swiss albino mice. The in vitro simulated study was performed to check the stability in simulated gastric fluids and simulated intestinal fluids and the release was found almost negligible. The in vitro anti-leishmanial activity of m-DDSLNs (1 µg/ml) has shown a maximum percentage of inhibition (96.22%) on intra-cellular amastigote growth of
L. donovani
. m-DDSLNs (20 mg/kg × 5 days,
p.o.
) has significantly (
P
 < 0.01) reduced the liver parasite burden as compared to miltefosine (3 mg/kg × 5 days,
p.o.
) in
L. donovani
-infected BALB/c mice. This work suggests that the superiority of as-prepared m-DDSLNs as a promising approach towards the oral delivery of anti-leishmanial drugs.